Clinical Trial Update: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 single-arm study evaluating carboplatin/gemcitabine with BSI-201 in platinum-sensitive recurrent ovarian cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BSI-201 (Iniparib) (iniparib)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sanofi | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED